

Isaac Garcia-murillas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1525194/publications.pdf>

Version: 2024-02-01

41
papers

5,615
citations

159585

30
h-index

265206

42
g-index

42
all docs

42
docs citations

42
times ranked

7752
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 302ra133.	12.4	889
2	Plasma <i>ESR1</i> Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2961-2968.	1.6	573
3	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2016, 76, 2301-2313.	0.9	509
4	Analysis of <i>ESR1</i> mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 313ra182.	12.4	460
5	The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. <i>Cancer Discovery</i> , 2018, 8, 1390-1403.	9.4	397
6	Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. <i>Nature Communications</i> , 2018, 9, 896.	12.8	305
7	Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1. <i>Cancer Discovery</i> , 2012, 2, 524-539.	9.4	261
8	Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1473.	7.1	237
9	Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6708-6720.	7.0	194
10	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , 2015, 21, 4586-4596.	7.0	171
11	Noninvasive Detection of <i>HER2</i> Amplification with Plasma DNA Digital PCR. <i>Clinical Cancer Research</i> , 2013, 19, 3276-3284.	7.0	157
12	Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. <i>Annals of Oncology</i> , 2018, 29, 145-153.	1.2	114
13	Discovery of naturally occurring <i>ESR1</i> mutations in breast cancer cell lines modelling endocrine resistance. <i>Nature Communications</i> , 2017, 8, 1865.	12.8	108
14	Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. <i>Annals of Oncology</i> , 2019, 30, 945-952.	1.2	103
15	Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. <i>British Journal of Cancer</i> , 2017, 117, 876-883.	6.4	98
16	<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials. <i>Clinical Cancer Research</i> , 2020, 26, 5172-5177.	7.0	82
17	lazar0 Encodes a Lipid Phosphate Phosphohydrolase that Regulates Phosphatidylinositol Turnover during <i>Drosophila</i> Phototransduction. <i>Neuron</i> , 2006, 49, 533-546.	8.1	73
18	Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. <i>Clinical Cancer Research</i> , 2020, 26, 608-622.	7.0	71

#	ARTICLE	IF	CITATIONS
19	Rhabdomere biogenesis in <i>Drosophila</i> photoreceptors is acutely sensitive to phosphatidic acid levels. <i>Journal of Cell Biology</i> , 2009, 185, 129-145.	5.2	67
20	Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2022-2034.	4.1	66
21	Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 309-317.	6.3	60
22	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, 2423.	12.8	54
23	Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. <i>Clinical Chemistry</i> , 2019, 65, 1405-1413.	3.2	53
24	Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. <i>PLoS ONE</i> , 2015, 10, e0139074.	2.5	50
25	Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6026-6034.	7.0	50
26	The genomic landscape of oesophagogastric junctional adenocarcinoma. <i>Journal of Pathology</i> , 2013, 231, 301-310.	4.5	42
27	Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer. <i>European Journal of Cancer</i> , 2018, 103, 165-175.	2.8	40
28	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. <i>Cancer Discovery</i> , 2021, 11, 92-107.	9.4	36
29	Cellular apoptosis susceptibility (chromosome segregation like, CSE1L) gene is a key regulator of apoptosis, migration and invasion in colorectal cancer. <i>Journal of Pathology</i> , 2012, 228, 471-481.	4.5	33
30	Determination of HER2 Amplification Status on Tumour DNA by Digital PCR. <i>PLoS ONE</i> , 2013, 8, e83409.	2.5	33
31	An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer. <i>Oncogene</i> , 2014, 33, 2478-2486.	5.9	30
32	The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4763-4770.	7.0	30
33	Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis. <i>Clinical Cancer Research</i> , 2022, 28, 1180-1191.	7.0	30
34	Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0165023.	2.5	29
35	Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. <i>Breast Cancer Research</i> , 2014, 16, R68.	5.0	26
36	Functional INAD complexes are required to mediate degeneration in photoreceptors of the <i>Drosophila</i> rdgA mutant. <i>Journal of Cell Science</i> , 2005, 118, 1373-1384.	2.0	22

#	ARTICLE	IF	CITATIONS
37	Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC). <i>Frontiers in Oncology</i> , 2020, 10, 505.	2.8	21
38	PIK3CA mutation enrichment and quantitation from blood and tissue. <i>Scientific Reports</i> , 2020, 10, 17082.	3.3	15
39	Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. <i>British Journal of Cancer</i> , 2019, 120, 247-255.	6.4	13
40	Assessing HER2 Amplification in Plasma cfDNA. <i>Methods in Molecular Biology</i> , 2018, 1768, 161-172.	0.9	9
41	Clinical Benefit of Circulating Tumor DNA Analysis in Follow-up of Patients With Early-Stage Breast Cancer—Reply. <i>JAMA Oncology</i> , 2020, 6, 439.	7.1	2